NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS
In its many embodiments, the present invention provides a novel class of pyrimidine analogs of formula (V) as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discus...
Gespeichert in:
Hauptverfasser: | , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; spa |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | In its many embodiments, the present invention provides a novel class of pyrimidine analogs of formula (V) as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the activator as well as the combination and pharmaceutical kits.
En sus muchas modalidades, la presente invención provee una clase novedosa de análogos de pirimidina de fórmula (V) como moduladores de mecanismo objetivo de los puntos de control del ciclo celular; los cánceres y/o enfermedades pueden tratarse por medio de la administración de un modulador de punto de control del ciclo celular de la invención; también se describen las combinaciones adecuadas del modulador de punto de control del ciclo celular con un inhibidor de cinasa de punto de control para producir apoptosis sinérgica en células cancerosas; la invención incluye métodos para tratar cáncer al administrar la combinación del modulador del punto de control del ciclo celular y el inhibidor de cinasas de punto de control, las composiciones farmacéuticas comprenden el activador así como la combinación y kits farmacéuticos. |
---|